Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

BACKGROUND: Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for infants in their first RSV season and for its pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Kieffer, Alexia, Beuvelet, Matthieu, Sardesai, Aditya, Musci, Robert, Milev, Sandra, Roiz, Julie, Lee, Jason K H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Supplement Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377043/
https://www.ncbi.nlm.nih.gov/pubmed/35968866
http://dx.doi.org/10.1093/infdis/jiac216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377043/
https://www.ncbi.nlm.nih.gov/pubmed/35968866
http://dx.doi.org/10.1093/infdis/jiac216

Ejemplares similares